¼¼°èÀÇ POC(Point-Of-Care) Ç÷´ç °Ë»ç ½ÃÀå
Point-of-Care Glucose Testing
»óǰÄÚµå : 1784018
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 201 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,150,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,452,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

POC(Point-Of-Care) Ç÷´ç °Ë»ç ¼¼°è ½ÃÀåÀº 2030³â±îÁö 41¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 34¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â POC(Point-Of-Care) Ç÷´ç °Ë»ç ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 3.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 41¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Accu Check Aviva Meter´Â CAGR 4.1%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 11¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Onetouch Verio Flex ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 3.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 9¾ï 1,650¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.4%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ POC(Point-Of-Care) Ç÷´ç °Ë»ç ½ÃÀåÀº 2024³â¿¡ 9¾ï 1,650¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 8¾ï 1,940¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.4%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.3%¿Í 2.5%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 1.9%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ POC(Point-Of-Care) Ç÷´ç °Ë»ç ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÇöÀå Ç÷´ç ÃøÁ¤ÀÌ ´ç´¢º´ °ü¸®¿¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

POC(Point-Of-Care) Ç÷´ç °Ë»ç´Â ´ç´¢º´ °ü¸®, ÀÀ±ÞÀÇ·á, ÁßȯÀÚ Ä¡·á ÇöÀå¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, ÀÇ·áÁø°ú ȯÀÚ°¡ ½Ç½Ã°£À¸·Î Ä¡·á ¹æÄ§À» °áÁ¤ÇÒ ¼ö ÀÖ´Â Ç÷´ç ¼öÄ¡¸¦ Áï°¢ÀûÀ¸·Î ÃøÁ¤ÇÕ´Ï´Ù. PoC Ç÷´ç ÃøÁ¤±â´Â ½Ã·á ó¸® ½Ã°£ÀÌ ÇÊ¿äÇÑ ±âÁ¸ ½ÇÇè½Ç ±â¹Ý Ç÷´ç °Ë»ç¿Í ´Þ¸® º´¿ø, Áø·á¼Ò, ¿Ü·¡ ȯÀÚ, ½ÉÁö¾î °¡Á¤ ȯ°æ¿¡¼­µµ ÇöÀå¿¡¼­ ½Å¼ÓÇÏ°Ô Ç÷´çÀ» ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü ¼¼°èÀûÀ¸·Î ´ç´¢º´ À¯º´·üÀÇ Áõ°¡´Â POC Ç÷´ç °Ë»çÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ±¹Á¦´ç´¢º´¿¬¸Í(IDF)¿¡ µû¸£¸é, Àü ¼¼°èÀûÀ¸·Î 5¾ï 3,700¸¸ ¸í ÀÌ»óÀÇ ¼ºÀÎÀÌ ´ç´¢º´À» ¾Î°í ÀÖÀ¸¸ç, ÀÌ ¼ýÀÚ´Â ÇâÈÄ ¸î ³â µ¿¾È Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. È¿°úÀûÀÎ Ç÷´ç ¸ð´ÏÅ͸µ°ú Ç÷´ç Á¶ÀýÀº ÀúÇ÷´ç, ÄÉÅæ»êÁõ, ½ÉÇ÷°üÁúȯ°ú °°Àº ÇÕº´ÁõÀ» ¿¹¹æÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇϸç, PoC Ç÷´ç °Ë»ç´Â ÀÏ»óÀûÀÎ ´ç´¢º´ Ä¡·áÀÇ ÇʼöÀûÀÎ ºÎºÐÀÌ µÇ¾ú½À´Ï´Ù.

ÀÚ°¡ Ç÷´ç ÃøÁ¤(SMBG) ÀåÄ¡¿Í ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ(CGM) ½Ã½ºÅÛÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´ç´¢º´ ȯÀÚ´Â Ç÷´ç ¼öÄ¡¸¦ ÀÚÁÖ ÃßÀûÇÏ°í ±×¿¡ µû¶ó »ýȰ½À°ü ¹× ¾à¹° Ä¡·á¸¦ Á¶Á¤ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ º´¿ø°ú ÀÀ±Þ½ÇÀº ÀúÇ÷´ç ¹× °íÇ÷´çÀ» ½Å¼ÓÇÏ°Ô °¨ÁöÇÏ¿© Áï°¢ÀûÀÎ Ä¡·á °³ÀÔ°ú ȯÀÚ °á°ú °³¼±À» º¸ÀåÇϱâ À§ÇØ PoC Ç÷´ç ÃøÁ¤±â¿¡ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀüÀº POC Ç÷´ç °Ë»ç¸¦ ¾î¶»°Ô °³¼±Çϰí Àִ°¡?

POC Ç÷´ç °Ë»ç ½ÃÀåÀº ¹ÙÀÌ¿À¼¾¼­ ±â¼ú, Ä¿³ØÆ¼µå ¼Ö·ç¼Ç, ºñħ½ÀÀû Ç÷´ç ¸ð´ÏÅ͸µ ±â¼úÀÇ ¹ßÀüÀ¸·Î ºü¸£°Ô ÁøÈ­Çϰí ÀÖ½À´Ï´Ù.

°¡Àå Áß¿äÇÑ ±â¼ú Çõ½Å Áß Çϳª´Â ¹«¼± ¿¬°á°ú µðÁöÅÐ °Ç°­ ¼Ö·ç¼ÇÀÇ ÅëÇÕÀÔ´Ï´Ù. ÃֽŠPoC Ç÷´çÃøÁ¤±â´Â ºí·çÅõ½º, Wi-Fi, ¸ð¹ÙÀÏ ¾Û ȣȯ¼ºÀ» °®Ãß°í ÀÖÀ¸¸ç, ÀüÀÚ ÀÇ·á ±â·Ï(EHR), Ŭ¶ó¿ìµå ±â¹Ý Ç÷§Æû, ´ç´¢º´ °ü¸® ¾ÖÇø®ÄÉÀ̼ÇÀ¸·Î ¿øÈ°ÇÑ µ¥ÀÌÅÍ Àü¼ÛÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ ±â´ÉÀ» ÅëÇØ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ(RPM) ¹× ÀÇ»ç¿Í ȯÀÚÀÇ Çù¾÷ÀÌ °¡´ÉÇØÁ® º¸´Ù Àû±ØÀûÀ̰í È¿À²ÀûÀÎ ´ç´¢º´ °ü¸®°¡ °¡´ÉÇØÁý´Ï´Ù.

¶Ç ´Ù¸¥ ȹ±âÀûÀÎ ¹ßÀüÀº ºñħ½ÀÀû, ÃÖ¼Òħ½ÀÀû Ç÷´ç ¸ð´ÏÅ͸µ ±â±âÀÇ °³¹ßÀÔ´Ï´Ù. ±âÁ¸ÀÇ Ç÷´ç ÃøÁ¤Àº ¼Õ°¡¶ôÀ» Âñ·¯¾ß Çϱ⠶§¹®¿¡ ȯÀÚ¿¡°Ô °íÅ뽺·´°í ºÒÆíÇÕ´Ï´Ù. ±â¾÷µéÀº ÇöÀç ¿þ¾î·¯ºí ¹ÙÀÌ¿À¼¾¼­, ¶¡À» ÀÌ¿ëÇÑ Ç÷´ç °¨Áö, Àû¿Ü¼±À» ÀÌ¿ëÇØ ÇǺο¡¼­ Ç÷´ç ¼öÄ¡¸¦ ÃøÁ¤ÇÏ´Â ±¤ÇÐ½Ä Ç÷´ç ¼¾¼­¸¦ ÀÌ¿ëÇÑ ¹Ù´Ã ¾ø´Â Ç÷´ç ¸ð´ÏÅ͸µ¿¡ ÁÖ¸ñÇϰí ÀÖ½À´Ï´Ù. ºñħ½ÀÀû Ç÷´ç °Ë»ç´Â ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀÌ°í »ç¿ëÀÚ °æÇèÀ» °³¼±ÇÔÀ¸·Î½á ´ç´¢º´ °ü¸®¿¡ Çõ¸íÀ» °¡Á®¿Ã °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

Áö¼ÓÀû Ç÷´ç ¸ð´ÏÅ͸µ(CGM) ½Ã½ºÅÛÀÇ ¹ßÀüµµ ½ÃÀåÀ» ÀçÆíÇϰí ÀÖ½À´Ï´Ù. ÀÏȸ¼º ÃøÁ¤°ªÀ» Á¦°øÇÏ´Â ±âÁ¸ PoC Ç÷´ç ÃøÁ¤±â¿Í ´Þ¸® CGMÀº Æ®·»µå ºÐ¼®°ú ÀúÇ÷´ç ¶Ç´Â °íÇ÷´ç °æ°í¸¦ ÅëÇØ ½Ç½Ã°£ Ç÷´ç ¸ð´ÏÅ͸µÀ» Á¦°øÇÕ´Ï´Ù. Abbott(FreeStyle Libre), Dexcom(G6 ¹× G7), Medtronic(Guardian Connect) µî ÁÖ¿ä Á¦Á¶¾÷üµéÀº ¼¾¼­ ÀåÂø ½Ã°£ ¿¬Àå, Á¤È®µµ Çâ»ó, Àν¶¸° ÆßÇÁ¿ÍÀÇ ÅëÇÕÀ» À§ÇØ CGM ±â¼úÀ» Áö¼ÓÀûÀ¸·Î °³¼±Çϰí ÀÖ½À´Ï´Ù. °³¼±Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, AI ±â¹Ý Ç÷´ç ºÐ¼® ¹× ¿¹Ãø ¾Ë°í¸®ÁòÀº Ç÷´ç ¸ð´ÏÅ͸µÀÇ Á¤È®µµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ±â°è ÇнÀ ¸ðµ¨Àº ÇöÀç Ç÷´ç Ãß¼¼¸¦ ºÐ¼®Çϰí, º¯µ¿¼ºÀ» ¿¹ÃøÇϰí, Àν¶¸° Åõ¿©, ½Ä»ç °èȹ, ½Åü Ȱµ¿ Á¶Á¤¿¡ ´ëÇÑ °³ÀÎÈ­ µÈ ±ÇÀå »çÇ×À» Á¦°ø ÇÒ ¼ö ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ PoC Ç÷´ç °Ë»ç ¼Ö·ç¼ÇÀº ÇÕº´ÁõÀ» ÁÙÀ̰í, Ç÷´ç Á¶ÀýÀ» °³¼±Çϸç, ¸ÂÃãÇü ´ç´¢º´ °ü¸®¸¦ Áö¿øÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

POC Ç÷´ç °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ÀÇ·á ¹× ÀçÅÃÀÇ·á ÇöÀå¿¡¼­ Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

´ç´¢º´, ´ë»ç ÀÌ»ó, »ýȰ½À°üº´ÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó º´¿ø, ¿Ü·¡ Áø·á¼Ò, ÀçÅà °£È£ ÇöÀå¿¡¼­ POC Ç÷´ç °Ë»ç°¡ ³Î¸® äÅõǰí ÀÖ½À´Ï´Ù.

¿ø°ÝÀÇ·á¿Í µðÁöÅÐ Çコ Ç÷§ÆûÀÇ È®´ëµµ POC Ç÷´ç °Ë»ç ¼Ö·ç¼ÇÀÇ ¼ö¿ä È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÇöÀç ¸¹Àº ¿ø°ÝÀÇ·á ¼­ºñ½º Á¦°øÀÚµéÀº Ç÷´ç ¸ð´ÏÅ͸µ µ¥ÀÌÅ͸¦ °¡»ó Áø·á¿Í ÅëÇÕÇÏ¿© °íÀ§Ç豺 ȯÀÚÀÇ ¿ø°Ý ´ç´¢º´ °ü¸® ¹× Á¶±â °³ÀÔÀ» °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.

POC Ç÷´ç °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

POC Ç÷´ç °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ´ç´¢º´ À¯º´·ü Áõ°¡, Àû±ØÀûÀÎ °Ç°­ °ü¸®¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀÎ½Ä Áõ°¡·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù.

Ç÷´ç ¸ð´ÏÅ͸µ ±â¼úÀÇ Áö¼ÓÀûÀÎ ±â¼ú Çõ½Å, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀÇ Ã¤Åà Ȯ´ë, ÀÇ·á ¹× °¡Á¤ ȯ°æ¿¡¼­ÀÇ Àû¿ë È®´ë¿¡ µû¶ó POC Ç÷´ç °Ë»ç ½ÃÀåÀº ºñ¾àÀûÀÎ ¼ºÀåÀ» ÀÌ·ê °ÍÀÔ´Ï´Ù. Ä¿³ØÆ¼µå Çコ ¼Ö·ç¼Ç, AI ±â¹Ý Áø´Ü, ȯÀÚ Áß½ÉÀÇ ´ç´¢º´ °ü¸® Àü·«ÀÌ ¹ßÀüÇÔ¿¡ µû¶ó, PoC Ç÷´ç °Ë»ç´Â Àü ¼¼°èÀûÀ¸·Î °³ÀÎÈ­µÈ µ¥ÀÌÅÍ ±â¹Ý ÇコÄɾîÀÇ ÇÙ½ÉÀÌ µÉ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

Á¦Ç°(Accu Check Aviva Meter, Onetouch Verio Flex, i-STAT, Bayer Contour Blood Glucose Monitoring System, Freestyle Lite, True Metrix, Accu-Chek Inform II, StatStrip, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Point-of-Care Glucose Testing Market to Reach US$4.1 Billion by 2030

The global market for Point-of-Care Glucose Testing estimated at US$3.4 Billion in the year 2024, is expected to reach US$4.1 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Accu Check Aviva Meter, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Onetouch Verio Flex segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$916.5 Million While China is Forecast to Grow at 6.4% CAGR

The Point-of-Care Glucose Testing market in the U.S. is estimated at US$916.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$819.4 Million by the year 2030 trailing a CAGR of 6.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Point-of-Care Glucose Testing Market - Key Trends & Drivers Summarized

Why Is Point-of-Care Glucose Testing Essential in Diabetes Management?

Point-of-care (PoC) glucose testing plays a crucial role in diabetes management, emergency care, and critical care settings, providing immediate blood glucose readings that enable healthcare providers and patients to make real-time treatment decisions. Unlike traditional laboratory-based glucose tests, which require sample processing time, PoC glucose meters allow for rapid, on-the-spot glucose monitoring in hospitals, clinics, ambulatory settings, and even home environments.

The global rise in diabetes prevalence is one of the major factors driving the adoption of PoC glucose testing. According to the International Diabetes Federation (IDF), over 537 million adults worldwide have diabetes, and this number is expected to grow significantly in the coming years. Effective glucose monitoring and glycemic control are critical in preventing complications such as hypoglycemia, ketoacidosis, and cardiovascular diseases, making PoC glucose testing an integral part of routine diabetes care.

The increasing adoption of self-monitoring blood glucose (SMBG) devices and continuous glucose monitoring (CGM) systems has empowered diabetic patients to track their glucose levels frequently and make lifestyle or medication adjustments accordingly. Additionally, hospitals and emergency departments rely on PoC glucose meters for rapid hypoglycemia and hyperglycemia detection, ensuring immediate therapeutic interventions and improved patient outcomes.

How Are Technological Advancements Improving PoC Glucose Testing?

The PoC glucose testing market is rapidly evolving with advancements in biosensor technology, connectivity solutions, and non-invasive glucose monitoring techniques.

One of the most significant innovations is the integration of wireless connectivity and digital health solutions. Modern PoC glucose meters are now equipped with Bluetooth, Wi-Fi, and mobile app compatibility, allowing seamless data transmission to electronic health records (EHRs), cloud-based platforms, and diabetes management applications. This feature enables remote patient monitoring (RPM) and physician-patient collaboration, making diabetes management more proactive and efficient.

Another breakthrough is the development of non-invasive and minimally invasive glucose monitoring devices. Traditional blood glucose testing requires finger-pricking, which can be painful and inconvenient for patients. Companies are now focusing on needle-free glucose monitoring using wearable biosensors, sweat-based glucose detection, and optical glucose sensors that utilize infrared light to measure glucose levels through the skin. Non-invasive glucose testing is expected to revolutionize diabetes management by enhancing patient adherence and improving user experience.

Advancements in continuous glucose monitoring (CGM) systems are also reshaping the market. Unlike traditional PoC glucose meters that provide single-time readings, CGMs offer real-time glucose monitoring with trend analysis and alerts for hypoglycemia or hyperglycemia. Leading manufacturers, such as Abbott (FreeStyle Libre), Dexcom (G6 and G7), and Medtronic (Guardian Connect), are continuously improving CGM technology to offer longer sensor wear, improved accuracy, and integration with insulin pumps.

Additionally, AI-driven glucose analytics and predictive algorithms are enhancing the precision of glucose monitoring. Machine learning models can now analyze glucose trends, predict fluctuations, and provide personalized recommendations for insulin dosing, meal planning, and physical activity adjustments. AI-powered PoC glucose testing solutions are expected to reduce complications, improve glycemic control, and support personalized diabetes management.

Why Is Demand for PoC Glucose Testing Growing Across Healthcare and Homecare Settings?

The increasing prevalence of diabetes, metabolic disorders, and lifestyle-related diseases has led to the widespread adoption of PoC glucose testing in hospitals, outpatient clinics, and homecare settings.

The expansion of telemedicine and digital health platforms has also contributed to the growing demand for PoC glucose testing solutions. Many telehealth providers now integrate glucose monitoring data with virtual consultations, enabling remote diabetes management and early intervention for high-risk patients.

What Factors Are Driving the Growth of the PoC Glucose Testing Market?

The growth in the PoC glucose testing market is driven by technological advancements, increasing diabetes prevalence, and rising consumer awareness about proactive healthcare.

With continuous innovations in glucose monitoring technology, increasing adoption of remote patient monitoring, and expanding applications in healthcare and home settings, the PoC glucose testing market is set for exponential growth. As connected health solutions, AI-driven diagnostics, and patient-centered diabetes management strategies evolve, PoC glucose testing will remain a cornerstone of personalized, data-driven healthcare worldwide.

SCOPE OF STUDY:

The report analyzes the Point-of-Care Glucose Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Accu Check Aviva Meter, Onetouch Verio Flex, i-STAT, Bayer Contour Blood Glucose Monitoring System, Freestyle Lite, True Metrix, Accu-Chek Inform II, StatStrip, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â